PMID- 32126517 OWN - NLM STAT- MEDLINE DCOM- 20210201 LR - 20210201 IS - 1879-0593 (Electronic) IS - 1368-8375 (Linking) VI - 103 DP - 2020 Apr TI - Prognostic factors and outcomes of multimodality treatment in olfactory neuroblastoma. PG - 104618 LID - S1368-8375(20)30054-3 [pii] LID - 10.1016/j.oraloncology.2020.104618 [doi] AB - OBJECTIVE: The clinical data on olfactory neuroblastomas (ONBs) are scarce owing to their rarity. This study aimed to assess the potential prognostic factors, outcomes, and optimal treatment strategies in patients with ONB. METHODS AND MATERIALS: The data of 217 patients with ONB between 1991 and 2019 were retrospectively reviewed. Long-term survival, potential prognostic factors, and outcomes with combined treatment strategies were analyzed. RESULTS: All patients received radiotherapy (RT); 185 patients underwent surgery, and 139 patients received chemotherapy. The 5-year overall survival (OS), progression-free survival (PFS), locoregional failure-free survival (LRFS), and distant metastasis-free survival (DMFS) of the entire cohort were 80.0%, 79.0%, 79.3%, and 80%, respectively. On univariate analyses, R0/R1 resection, early Kadish stage, negative lymph nodes, absence of orbital invasion, and administration of surgery with RT were found to be favorable factors. Conversely, combined sequential treatment with surgery, RT, and chemotherapy was not associated with survival. Multivariate analysis demonstrated lymph node status, orbital invasion, and the combination of surgery and RT to be independent prognostic factors. CONCLUSIONS: Patients with ONB, who had lymph node metastases, orbital invasion diseases, advanced Kadish stages, R2 resection margins, and received RT alone, had poor outcomes. Combined administration of surgery and RT may be a potentially useful strategy in patients with advanced Kadish stages; the role of chemotherapy in these stages requires further evaluation. CI - Copyright (c) 2020 Elsevier Ltd. All rights reserved. FAU - Song, Xinmao AU - Song X AD - Department of Radiation Oncology, Eye, Ear, Nose & Throat Hospital of Fudan University, 83 Fenyang Road, Shanghai 200031, China. FAU - Wang, Jie AU - Wang J AD - Department of E.N.T., Eye, Ear, Nose & Throat Hospital of Fudan University, 83 Fenyang Road, Shanghai 200031, China. FAU - Wang, Shengzi AU - Wang S AD - Department of Radiation Oncology, Eye, Ear, Nose & Throat Hospital of Fudan University, 83 Fenyang Road, Shanghai 200031, China. Electronic address: shengziwang@126.com. FAU - Yan, Li AU - Yan L AD - Department of Radiation Oncology, Eye, Ear, Nose & Throat Hospital of Fudan University, 83 Fenyang Road, Shanghai 200031, China. FAU - Li, Yi AU - Li Y AD - Department of Oncology, 920th Hospital of Joint Logistics Support Force, 212 Daguan Road, Kunming 650032, China. Electronic address: liyi3443@hotmail.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200229 PL - England TA - Oral Oncol JT - Oral oncology JID - 9709118 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Child MH - Combined Modality Therapy/*methods MH - Esthesioneuroblastoma, Olfactory/*drug therapy/mortality MH - Female MH - Humans MH - Male MH - Middle Aged MH - Prognosis MH - Treatment Outcome MH - Young Adult OTO - NOTNLM OT - Kadish stage OT - Olfactory neuroblastoma OT - Orbital invasion OT - Prognostic factors OT - Treatment strategy COIS- Declaration of Competing Interest The authors have no personal or institutional conflicts of interest. EDAT- 2020/03/04 06:00 MHDA- 2021/02/02 06:00 CRDT- 2020/03/04 06:00 PHST- 2020/01/01 00:00 [received] PHST- 2020/02/13 00:00 [revised] PHST- 2020/02/22 00:00 [accepted] PHST- 2020/03/04 06:00 [pubmed] PHST- 2021/02/02 06:00 [medline] PHST- 2020/03/04 06:00 [entrez] AID - S1368-8375(20)30054-3 [pii] AID - 10.1016/j.oraloncology.2020.104618 [doi] PST - ppublish SO - Oral Oncol. 2020 Apr;103:104618. doi: 10.1016/j.oraloncology.2020.104618. Epub 2020 Feb 29.